TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03137784

Intervention type: DRUG
Group type: OTHER
Intervention: NVA237 (glycopyrronium bromide)
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

Intervention type: DRUG
Group type: OTHER
Intervention: NVA237 (glycopyrronium bromide)
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

Intervention type: DRUG
Group type: OTHER
Intervention: NVA237 (glycopyrronium bromide)
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

Intervention type: DRUG
Group type: OTHER
Intervention: NVA237 (glycopyrronium bromide)
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

Intervention type: DRUG
Group type: OTHER
Intervention: NVA237 (glycopyrronium bromide)
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

Intervention type: DRUG
Group type: OTHER
Intervention: NVA237 (glycopyrronium bromide)
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In each treatment arm, patient will receive placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In each treatment arm, patient will receive placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In each treatment arm, patient will receive placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In each treatment arm, patient will receive placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In each treatment arm, patient will receive placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In each treatment arm, patient will receive placebo
Study: NCT02279485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Study: NCT01354145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Description: Chondroitin sulphate 1200 mg/day, 24 months treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg/day, 24 months treatment period
Study: NCT01962597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Study: NCT02265107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
Study: NCT01958385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placement of g-Cath EZ suture anchors

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide
Study: NCT02377570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype AA
Description: Hemodialysis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype BB
Description: Hemodialysis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERNOVA 400 dialyzer prototype CC
Description: Hemodialysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX CorDiax 80 dialyzer
Description: Hemodialysis
Study: NCT03444766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study: NCT01504633

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA/EPA and iron supplementation
Description: 24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA/EPA and iron supplementation
Description: 24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt
Study: NCT03395301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil
Description: Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
Study: NCT00867776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAHC Exercise Program Support Group
Description: 6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
Study: NCT03373032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stiper
Description: Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up
Description: Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
Study: NCT02275117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00858260

Intervention type: GENETIC
Intervention: blood sample
Description: Searching for Klotho variants in DNA
Study: NCT01327274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Mini-Mover Procedure (Magnimplant)
Description: This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
Study: NCT02376101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery less than 60 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery less than 60 minutes
Study: NCT02570581

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt
Study: NCT01693380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Control vaccine
Description: Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered.
Study: NCT02577770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: therapeutic acupuncture treatment with actual needles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: therapeutic acupuncture treatment with actual needles

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: therapeutic acupuncture treatment with actual needles

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg caffeine
Description: 8g coffee, po

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400mg caffeine
Description: 16g coffee, po

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated
Description: decaffeinated coffee, po
Study: NCT01280539

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: 3 weeks, 5 times a week, 60 minutes a day.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine
Study: NCT01280539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: 3 weeks, 5 times a week, 60 minutes a day.
Study: NCT04053751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed suctioning system
Description: a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
Study: NCT01420172

Intervention type: OTHER
Intervention: Data Collection
Description: Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
Study: NCT00171925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium / Vitamin D
Description: Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
Study: NCT02590562

Intervention type: OTHER
Intervention: Routine clinical practice
Study: NCT03035253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-305B83

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
Study: NCT04529369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle lobe only Photoselective vaporization of the prostate (PVP)
Description: Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete PVP
Description: Traditional Photoselective vaporization of the prostate PVP
Study: NCT03153072

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Assess the absorption of oral amiodarone
Description: Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine
Study: NCT03538184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Preparation of implant beds entirely with piezo surgery implant tips

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drill
Description: Preparation of implant beds entirely with conventional implant drills
Study: NCT04450628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgeon unblinded
Description: The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP 1.0 System EF-100
Description: The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication.
Study: NCT01158027

Intervention type: OTHER
Intervention: gait evaluation
Description: The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
Study: NCT00481312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Continuous Infusion
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine
Study: NCT00481312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Continuous Infusion
Study: NCT00824005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult stem cells
Description: Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
Study: NCT02836782

Intervention type: PROCEDURE
Intervention: Blood sample withdrawal
Description: Blood withdrawal for HIV-DNA or HCV resistance test

Intervention type: PROCEDURE
Intervention: Blood sample withdrawal
Description: Blood withdrawal for HIV-DNA or HCV resistance test
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Memantine
Study: NCT01510184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: Zevalin administered intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90-Zevalin
Description: Y-90-Zevalin administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-111 Zevalin
Description: In-111-Zevalin administered by intravenously.
Study: NCT03824275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F- DCFPyL PET/CT
Description: A CT scan using a radioactive marker to better image tumors